LPOXY Therapeutics: $28M Series A Sales Battle Card
LPOXY lands $28M Series A. Drill into Dr. Larry Sutton, pitch trial support & RWE to ramp your pipeline. Quick do-now checklist to fuel your next touch.
Published on
Do not index
Do not index
🚀 Battle Card: LPOXY Therapeutics
Quick trigger:
👤 Decision Maker in the News
- Dr. Larry Sutton, CEO 📧 larry@lpoxy.com
💡 Why It Matters
- This LPOXY Therapeutics sales trigger underscores investor confidence in non-antibiotic C. difficile prevention, accelerating partnerships for registrational trials. → Source
🎯 Core Pain Point
- High recurrence & hospital readmissions from C. difficile infections
- Rising antibiotic resistance limiting current treatment options
💰 What to Pitch
- Primary: Registrational trial support → Speed to FDA approval
- Expansion: Real-world evidence platform → Data-driven payer/provider buy-in
🗺️ Quick Context
- HQ: Platte City, MO
- Employees: ≈ 25
- Rev: ≈ $0.5M
- Website: https://www.lpoxy.com/
🤼 Competitive Intel
*Which other vendors you’ll probably face to win LPOXY Therapeutics’ business.*
- LabCorp/Covance — CRO / Clinical Trial Services
- Unique edge: Extensive global trial network
- Evaluated by CEO & Head of Clinical for scale
- Parexel — CRO / Clinical Trial Services
- Unique edge: Integrated regulatory consulting
- Evaluated by CMO & VP Regulatory Affairs
- ICON — CRO / eClinical Solutions
- Unique edge: Advanced data management platform
- Evaluated by VP Ops & Data Management
- IQVIA — CRO / Real-World Evidence
- Unique edge: Largest RWE database
- Evaluated by VP Medical Affairs for post-trial insights
✅ Do-Now Checklist
Connect with Dr. Larry Sutton on LinkedIn
Generate email + DM using the LPOXY Therapeutics sales trigger insight and send first touch
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Capitalize on this LPOXY Therapeutics sales trigger every time a biotech hits Series A.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑<your company>❑
OFFER_BRIEF = ❑Registrational trial support❑
PROOF_METRIC = ❑≈ TBD❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Dr. Larry
COMPANY = LPOXY Therapeutics
DEPT = ≈ TBD
SIZE = 25
BOTTLENECK = High recurrence & hospital readmissions
EVENT = Series A financing
DETAIL = $28M Series A financing
PAIN = High recurrence & hospital readmissions from C. difficile infections
SRC = https://vcnewsdaily.com/lpoxy-therapeutics/venture-capital-funding/cvgwblcsqg
SIM_CO = LabCorp
WIN_METRIC = ≈ TBD
NEXT_SIZE = 50
EMP_EST = ≈ 25
REV_EST = ≈ $0.5M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: 25-person ≈ TBD
Dr. Larry—noticed your ≈ TBD team is ≈ 25.
That’s when High recurrence & hospital readmissions slows growth.
We helped LabCorp fix this with Registrational trial support.
Result: ≈ TBD.
Quick call?
PS—next bottleneck hits ≈ 50.
DM ≤45 words, TONE:
Saw your post about $28M Series A financing — High recurrence & hospital readmissions from C. difficile infections.
Registrational trial support. ≈ TBD.
Quick chat?